13,403 reports of this reaction
2.6% of all GOLIMUMAB reports
#3 most reported adverse reaction
PAIN is the #3 most commonly reported adverse reaction for GOLIMUMAB, manufactured by Janssen Biotech, Inc.. There are 13,403 FDA adverse event reports linking GOLIMUMAB to PAIN. This represents approximately 2.6% of all 511,555 adverse event reports for this drug.
Patients taking GOLIMUMAB who experience pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PAIN is a less commonly reported adverse event for GOLIMUMAB, but still significant enough to appear in the safety profile.
In addition to pain, the following adverse reactions have been reported for GOLIMUMAB:
The following drugs have also been linked to pain in FDA adverse event reports:
PAIN has been reported as an adverse event in 13,403 FDA reports for GOLIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PAIN accounts for approximately 2.6% of all adverse event reports for GOLIMUMAB, making it one of the most commonly reported side effect.
If you experience pain while taking GOLIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.